![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Antileukoproteinase, Skin-derived
2. Elafin
3. Inhibitor Wap3, Protease
4. Peptidase Inhibitor 3, Skin Derived
5. Peptidase Inhibitor 3, Skin-derived
6. Protease Inhibitor 3, Skin Derived
7. Protease Inhibitor 3, Skin-derived
8. Protease Inhibitor Wap3
9. Skin Derived Antileukoproteinase
10. Skin-derived Antileukoproteinase
1. 820211-82-3
2. Elafin
3. Human Elafin
4. Tiprelestat [inn]
5. Trappin-2
6. Unii-78i8295690
7. Dtxsid00231519
8. Human Elafin (elastase-specific Inhibitor, Skin-derived Antileukoproteinase, Peptidase Inhibitor 3)
9. 78i8295690
Molecular Weight | 5999 g/mol |
---|---|
Molecular Formula | C254H416N72O75S10 |
XLogP3 | -25.6 |
Hydrogen Bond Donor Count | 74 |
Hydrogen Bond Acceptor Count | 93 |
Rotatable Bond Count | 115 |
Exact Mass | 5996.8225594 g/mol |
Monoisotopic Mass | 5994.8158498 g/mol |
Topological Polar Surface Area | 2550 Ų |
Heavy Atom Count | 411 |
Formal Charge | 0 |
Complexity | 15200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 58 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in inflammatory disorders (unspecified).
Treatment of oesophageal carcinoma
Protease Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)
Elafin is able to abrogate lipopolysaccharide-induced production of monocyte chemotactic protein 1 in monocytes by inhibiting AP-1 and NFkappaB activation. Due to its selective expression at mucosal surfaces as well as in alveolar macrophages, monocytes and neutrophils, the ability of Elafin to inhibit the lipopolysaccharide signaling pathway may be important in disease states such as cystic fibrosis, pneumonia, and acute respiratory distress syndrome. The inhibition of two key inflammatory pathways confirms the importance of Elafin as a mediator of the innate immune response.